Predictors of early mortality in patients with wild-type transthyretin amyloidosis

In this video, Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses the main predictors of early mortality in patients with wild-type transthyretin (ATTR) cardiac amyloidosis. Cardiac biomarkers such as cardiac troponin and NT-proBNP, along with patient age and performance status, help identify high-risk patients. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.